“The deal,” Newsweek reported, “ensures that drugs will be sold at reduced prices, many at the same price as overseas, and purchased through the new TrumpRx platform due to launch in January.” In other words, now that the Democrats have pushed all their midterm gambling chips onto the “affordability” square, President Trump is days away from opening up a website for people to buy common drugs at rock-bottom prices— a website with his name right in the URL. It requires little imagination to forecast that nearly every American over 18 years old will use that website at one time or another. They’d better have fast servers. The program will lower some popular drug costs to below co-pay prices (but only if the drugmakers give their drugs long, ridiculous-sounding, and difficult-to-pronounce names. Oh, wait.). Standout examples include: Boehringer Ingelheim will reduce the price of its Type II diabetes medicine, Jentadeuto, from $525 to only $55. Merck will reduce the price of its diabet